Document is current
Any future updates will be listed below
-
Authors
Ryu, Keun Woo
Fung, Tak Shun
Baker, Daphne C. https://orcid.org/0009-0000-5171-7958
Saoi, Michelle
Park, Jinsung
Febres-Aldana, Christopher A. https://orcid.org/0000-0002-4754-1344
Aly, Rania G.
Cui, Ruobing
Sharma, Anurag https://orcid.org/0000-0001-5345-8830
Fu, Yi
Jones, Olivia L.
Cai, Xin https://orcid.org/0000-0001-5238-6193
Pasolli, H. Amalia https://orcid.org/0000-0003-3899-3530
Cross, Justin R. https://orcid.org/0000-0002-6356-057X
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
Thompson, Craig B. https://orcid.org/0000-0003-3580-2751
- License Information
-
More Information
Article History
Received: 8 December 2023
Accepted: 2 October 2024
First Online: 6 November 2024
Competing interests
: C.M.R. has consulted regarding oncology drug development with Amgen, AstraZeneca, Chugai, D2G, Daiichi Sankyo, Hoffman-La Roche, Jazz and Legend, and serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli and Harpoon Therapeutics. C.B.T. is a founder of Agios Pharmaceuticals, and is on the board of directors of Regeneron and Charles River Laboratories. The remaining authors declare no competing interests.
